404 related articles for article (PubMed ID: 30048391)
1. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
3. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
4. Interventions for reducing inflammation in familial Mediterranean fever.
Yin X; Tian F; Wu B; Xu T
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
[TBL] [Abstract][Full Text] [Related]
5. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
6. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
8. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
Laskari K; Boura P; Dalekos GN; Garyfallos A; Karokis D; Pikazis D; Settas L; Skarantavos G; Tsitsami E; Sfikakis PP
J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
[TBL] [Abstract][Full Text] [Related]
9. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever.
Karabulut Y; Gezer HH; Öz N; Esen İ; Duruöz MT
Rheumatol Int; 2022 Dec; 42(12):2211-2219. PubMed ID: 36048189
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
Sag E; Akal F; Atalay E; Akca UK; Demir S; Demirel D; Batu ED; Bilginer Y; Ozen S
Rheumatology (Oxford); 2020 Nov; 59(11):3324-3329. PubMed ID: 32306038
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
16. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Atas N; Eroglu GA; Sodan HN; Ozturk BO; Babaoglu H; Satis H; Karadeniz H; Guler AA; Salman RB; Goker B; Ozturk MA; Haznedaroglu S; Tufan A
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):30-36. PubMed ID: 34251317
[TBL] [Abstract][Full Text] [Related]
18. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab.
Druyan A; Giat E; Livneh A; Grossman C; Ben-Zvi I; Lidar M
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):75-79. PubMed ID: 34369359
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O
Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
